BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Systemic Juvenile Idiopathic Arthritis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Systemic Juvenile Idi
 opathic Arthritis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02991469-5897@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Sarilumab: Phase 2 readout est. (NCT02991469)
DESCRIPTION:Sarilumab\, phase 2\, Systemic Juvenile Idiopathic Arthritis.\n
 Study: A Repeated Dose-finding Study of Sarilumab in Children and Adolesce
 nts With Systemic Juvenile Idiopathic Arthritis (SKYPS)\nEstimated primary
  completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sarilumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02991469
URL:https://assetmemo.bio/drug/sarilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
